Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorised as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site.... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyse the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customised advertisements based on the pages you visited previously and to analyse the effectiveness of the ad campaigns.

No cookies to display.

Post-grant review in Hatch-Waxman litigation

MARCH-APRIL 2019

Author

David Weingarten, Finnegan Henderson, Atlanta, GA
M.David.Weingarten@finnegan.com
Katherine Leonard, Finnegan Henderson, Atlanta, GA

Presentation

257th ACS National Meeting – Orlando
Tuesday, April 2, 2019, 10:30am-11:00am
Orange County Convention Center Room W308D
”Post-grant review in Hatch-Waxman litigation”

Abstract

The America Invents Act (AIA) made sweeping changes to the U.S. patent system, including the creation of administrative trial procedures to request review of the patentability of issued patents outside of patent litigation in federal court. Competitors in the pharmaceutical industry have used post-grant review proceedings, such as inter partes review (IPR), before the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board to challenge pharmaceutical companies’ patents as an alternative to litigation in federal court. This presentation will provide an overview of post-grant review proceedings, discuss the interplay between such challenges and patent infringement cases, and provide helpful strategies for pharmaceutical companies anticipating concurrent Hatch-Waxman litigation and post-grant review.